U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which ...

Mason Capital Management LLC’s Kenneth M Garschina has called the Spanish regulator’s attention to Grifols SA’s “severe lack of disclosure” as he tries to push for a board reshuffle.

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

Flat Footed today sent a letter to the Grifols Board of Directors. The full text of the letter follows: Dear Mr. Glanzmann, Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

BARCELONA, Spain, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a global healthcare company and leading producer of plasma ...